Synapse - Interventional Radiology Service

Results (58)

Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases

Journal Article

Shady, W.; Petre, E. N.; Vakiani, E.; Ziv, E.; Gonen, M.; Brown, K. T.; Kemeny, N. E.; Solomon, S. B.; Solit, D. B.; Sofocleous, C. T.
Oncotarget (2017)

Fulltext@MSK | Save

ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis

Journal Article

Bose, R.; Karthaus, W. R.; Armenia, J.; Abida, W.; Iaquinta, P. J.; Zhang, Z.; Wongvipat, J.; Wasmuth, E. V.; Shah, N.; Sullivan, P. S.; more...
Nature (2017)

Fulltext@MSK | Save

AKT inhibition in solid tumors with AKT1 mutations

Journal Article

Hyman, D. M.; Smyth, L. M.; Donoghue, M. T. A.; Westin, S. N.; Bedard, P. L.; Dean, E. J.; Bando, H.; El-Khoueiry, A. B.; Pérez-Fidalgo, J. A.; Mita, A.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: A phase Ib study of dasatinib plus ipilimumab

Journal Article

D'Angelo, S. P.; Shoushtari, A. N.; Keohan, M. L.; Dickson, M. A.; Gounder, M. M.; Chi, P.; Loo, J. K.; Gaffney, L.; Schneider, L.; Patel, Z.; more...
Clinical Cancer Research (2017)

Fulltext@MSK | Save

PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases

Journal Article

Ziv, E.; Bergen, M.; Yarmohammadi, H.; Boas, F. E.; Petre, E. N.; Sofocleous, C. T.; Yaeger, R.; Solit, D. B.; Solomon, S. B.; Erinjeri, J. P.
Oncotarget (2017)

Fulltext@MSK | Save

Gene signature associated with upregulation of the Wnt/β-catenin signaling pathway predicts tumor response to transarterial embolization

Journal Article

Ziv, E.; Yarmohammadi, H.; Boas, F. E.; Petre, E. N.; Brown, K. T.; Solomon, S. B.; Solit, D.; Reidy, D.; Erinjeri, J. P.
Journal of Vascular and Interventional Radiology (2017)

Fulltext@MSK | Save

Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT

Journal Article

Ulaner, G. A.; Hyman, D. M.; Ross, D. S.; Corben, A.; Chandarlapaty, S.; Goldfarb, S.; McArthur, H.; Erinjeri, J. P.; Solomon, S. B.; Kolb, H.; more...
Journal of Nuclear Medicine (2016)

Fulltext@MSK | Save

Genomic characterization of primary and metastatic prostate cancer (PC) using a targeted next-generation sequencing assay

Meeting Abstract

Abida, W.; Brennan, R.; Armenia, J.; Curtis, K. R.; Gopalan, A.; Arcila, M. E.; Danila, D. C.; Rathkopf, D. E.; Morris, M. J.; Slovin, S. F.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Meeting Abstract

Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
Cancer Research (2015)

Fulltext@MSK | Save

Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Meeting Abstract

Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
Cancer Research (2015)

Fulltext@MSK | Save